De Clercq Erik
Rega Institute for Medical Research, Leuven, Belgium.
Antivir Chem Chemother. 2019 Jan-Dec;27:2040206619829382. doi: 10.1177/2040206619829382.
AMD3100 (plerixafor, Mozobil®) was first identified as an anti-HIV agent specifically active against the T4-lymphotropic HIV strains, as it selectively blocked the CXCR4 receptor. Through interference with the interaction of CXCR4 with its natural ligand, SDF-1 (also named CXCL12), it also mobilized the CD34stem cells from the bone marrow into the peripheral blood stream. In December 2008, AMD3100 was formally approved by the US FDA for autologous transplantation in patients with Non-Hodgkin's Lymphoma or multiple myeloma. It may be beneficially used in various other malignant diseases as well as hereditary immunological disorders such as WHIM syndrome, and physiopathological processes such as hepatopulmonary syndrome.
AMD3100（普乐沙福，Mozobil®）最初被鉴定为一种抗HIV药物，对嗜T4淋巴细胞的HIV毒株具有特异性活性，因为它能选择性地阻断CXCR4受体。通过干扰CXCR4与其天然配体SDF-1（也称为CXCL12）的相互作用，它还能将骨髓中的CD34干细胞动员到外周血流中。2008年12月，AMD3100被美国食品药品监督管理局正式批准用于非霍奇金淋巴瘤或多发性骨髓瘤患者的自体移植。它也可能有益地用于各种其他恶性疾病以及遗传性免疫疾病，如WHIM综合征，以及生理病理过程，如肝肺综合征。
